OSP News

Blue Cross Complete CDC Recommends New Injectable HIV Prevention Drug

Posted: 11/03/2025

The Centers for Disease Control and Prevention (CDC) released new clinical guidance formally recommending the twice-a-year injectable lenacapavir as an additional option for HIV prevention in the United States. The U.S. Food and Drug Administration approved lenacapavir for HIV pre-exposure prophylaxis, or PrEP in June 2025. 

This is a significant step forward in expanding prevention options and reflects decades of research, partnership, and commitment to ending the HIV epidemic, according to the Michigan Department of Health and Human Services. 

The Clinical Recommendations for lenacapavir are an addition to the CDC’s current Clinical Guidance for PrEP, which includes daily oral pills or injectable cabotegravir, which is administered every two months. All FDA-approved PrEP options are highly effective in preventing HIV when taken as prescribed.

Click here to read the full announcement from Blue Cross Complete.

We value your privacy. We use cookies and other technologies to keep the web site reliable and secure, tailor your experience, and measure web site performance, as described in our Privacy Policy.

x

OSP Technical Support